Anxiety sufferers may soon have a new alternative natural treatment available to them with health and wellness company Fiji Kava (ASX: FIJ) to supply noble kava extract to BioCeuticals, a healthcare products company owned by Blackmores (ASX: BKL).

The supply agreement will provide BioCeuticals with noble kava extract to be used in their AnxioCalm products which will be co-branded to display Fiji Kava’s ‘Authentic Fiji Kava’ trademark. Products will then be distributed by BioCeuticals through their network of healthcare professionals in Australia and New Zealand to offer patients relief from mild anxiety, tension and stress. 

“This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava,” said Fiji Kava CEO, Zane Yoshida.  

“In particular, we are proud to support BioCeuticals with our water extracted Noble Fiji Kava, as allowed by the TGA in Australia. 

“Fiji Kava will continue to scale-up its production in Fiji to produce required inventory to meet the growing demand from the BioCeuticals licence agreement and other recent business development advancements such as ranging in Coles Supermarkets nationally.”

Through their 100% traceable supply chain, Fiji Kava was the first foriegn company approved by the Fijian Government to operate in the kava industry and focuses on bringing the health benefits of kava to the western world. 

With their products undergoing stringent testing to confirm their treatment capabilities, products are approved by top regulatory pharmaceutical bodies including the FDA in the United States and TGA in Australia.

Having listed on the ASX in 2018, Fiji Kava has since secured distribution deals with Coles Supermarkets in Australia and Green Cross Pharmacy in New Zealand, and are in the process of growing their presence in the United States via the Amazon marketplace. 

FIJ shares responded exceptionally well to news of the BioCeuticals supply agreement, opening at $0.125, a rise of 43% on their previous $0.087 close.